FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping

Medical Principles and Practice

Volumn 23, Issue 5, 2014, Pages 478-481

  Yeh, Yung Sung ^a,c,d   Huang, Meng Lin ^b   Chang, Se Fen ^c   Chen, Chin Fan ^a,c   Hu, Huang Ming ^c   Wang, Jaw Yuan ^c,d  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bevacizumab; FOLFIRI; Hyperbilirubinemia; Liver dysfunction; UGT1A1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; MONOCLONAL ANTIBODY; UGT1A1 ENZYME;

ABDOMINAL DISTENSION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; COLON ADENOCARCINOMA; COLON BIOPSY; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DECREASED APPETITE; DRUG DOSE ESCALATION; ENDOSCOPIC BIOPSY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER METASTASIS; MALE; MEDICAL HISTORY; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PROMOTER REGION; RECOMMENDED DRUG DOSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; COMPLICATION; GENETICS; LIVER NEOPLASMS; PATHOLOGY; SECONDARY;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; HYPERBILIRUBINEMIA; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 84927696312     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000358799     Document Type: Article

References (10)

1. Ishida H, Fujita K, Akiyama Y, et al: Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Jpn J Clin Oncol 2011; 41:617-623.
2. Sanli UA, Karabulut B, Uslu R, et al: Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Med Princ Pract 2006; 15:288-292.
3. Shimura T, Kataoka H, Hirata Y, et al: Meta-static colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy. J Gastrointest Cancer 2011; 42:68-72.
4. Cecchin E, Innocenti F, D'Andrea M, et al: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplo-types on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leu-covorin, and irinotecan. J Clin Oncol 2009; 27: 2457-2465.
5. Fakih MG: 5-Fluorouracil leucovorin and ox-aliplatin (FOLFOX) in the treatment of meta-static colon cancer with severe liver dysfunction. Oncology 2004; 67:222-224.
6. Venook AP, Enders Klein C, Fleming G, et al: A phase I and pharmacokinetic study of irino-tecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14:1783-1790.
7. Walia T, Quevedo JF, Hobday TJ, et al: Colorectal cancer patients with liver metasta-ses and severe hyperbilirubinemia: a consecutive series that explores the benefits and risks of chemotherapy. Ther Clin Risk Manag 2008; 4:1363-1366.
8. Marcuello E, Páez D, Paré L, et al: A genotype-directed phase I-IV dose-finding study of iri-notecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 2011; 105:53-57.
9. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779-4786.
10. Ribero D, Wang H, Donadon M, et al: Beva-cizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761-2767.